Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

conforma sa-nv - codeine 2 mg/g - syrup - 2,62 mg/ml - codeine 2 mg/g - opium alkaloids and derivatives

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

conforma sa-nv - codeine 2 mg/g - syrup - opium alkaloids and derivatives

United States - English - NLM (National Library of Medicine)

lannett company, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine anhydrous - unii:ux6owy2v7j) - codeine sulfate 15 mg - codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ s ee warnings and precautions ( 5.1 ) ] , reserve codeine sulfate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated. have not been tolerated, or are not expected to be tolerated. - have not provided adequate analgesia, or are not expected to provide adequate analgesia. have not provided adequate analgesia, or are not expected to provide adequate analgesia. codeine sulfate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ( 5.4 )] . - post-operative management in children younger than 18 years of age following tonsillect

Canada - English - Health Canada

purdue pharma - codeine (codeine monohydrate, codeine sulfate trihydrate) - tablet (extended-release) - 200mg - codeine (codeine monohydrate, codeine sulfate trihydrate) 200mg - opiate agonists

Canada - English - Health Canada

purdue pharma - codeine (codeine monohydrate, codeine sulfate trihydrate) - tablet (extended-release) - 100mg - codeine (codeine monohydrate, codeine sulfate trihydrate) 100mg - opiate agonists

Canada - English - Health Canada

purdue pharma - codeine (codeine monohydrate, codeine sulfate trihydrate) - tablet (extended-release) - 150mg - codeine (codeine monohydrate, codeine sulfate trihydrate) 150mg - opiate agonists

Canada - English - Health Canada

purdue pharma - codeine (codeine monohydrate, codeine sulfate trihydrate) - tablet (extended-release) - 50mg - codeine (codeine monohydrate, codeine sulfate trihydrate) 50mg - opiate agonists

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - codeine sulfate (unii: 11qv9bs0cb) (codeine - unii:q830pw7520) - codeine sulfate 60 mg - codeine sulfate is an opioid analgesic indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate. codeine sulfate is contraindicated in patients with known hypersensitivity to codeine or any components of the product. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. codeine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. codeine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. codeine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. enter section text here codeine sulfate is an opioid agonist and is a schedule ii controlled substance. codeine sulfate can be abused and is subject to criminal diversion.  drug addiction is characterized by compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm. drug addiction is

United States - English - NLM (National Library of Medicine)

nexgen pharma, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - codeine phosphate 54.3 mg - codeine phosphate and chlorpheniramine maleate is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. important limitations of use not indicated for pediatric patients under 18 years of age [see use in special population (8.4)] patients with known hypersensitivity to codeine, chlorpheniramine or any of the inactive ingredients of codeine phosphate and chlorpheniramine maleate. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. teratogenic effects pregnancy category c there are no adequate and well-controlled studies of codeine phosphate and chlorpheniramine maleate in pregnant women. reproductive toxicity studies have not been conducted with codeine phosphate and chlorpheniramine maleate; however, studies are available with individual active ingredients or related active ingredients. because animal reproduction studies are not always predictive of human response, co